Related Experiment Videos
Can we prevent in-stent restenosis?
Luis Garza1, Y Wady Aude, Jorge F Saucedo
1Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, 72205, USA. garzaluis@uams.edu
Current Opinion in Cardiology
|October 3, 2002
Summary
In-stent restenosis (ISR) after coronary stenting is a major issue. New drug-eluting stents show promise in preventing and treating ISR, offering hope for better patient outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomedical Engineering
Background:
- Stent placement is now standard for percutaneous coronary intervention, surpassing balloon angioplasty due to superior outcomes.
- In-stent restenosis (ISR), a significant complication, affects 10-50% of patients and is linked to risk factors like small vessel size, long lesions, and diabetes.
Purpose of the Study:
- To review current and emerging management strategies for in-stent restenosis (ISR).
- To evaluate the efficacy of various therapeutic approaches, including mechanical, systemic drug, and intracoronary radiation therapies.
- To highlight the potential of drug-eluting stent technology in addressing ISR.
Main Methods:
- Literature review of studies on in-stent restenosis (ISR) management.
- Analysis of intravascular ultrasound findings regarding ISR etiology (neointimal proliferation).
- Comparative assessment of different treatment modalities for ISR.
Main Results:
- Mechanical and systemic drug therapies for ISR have yielded disappointing results.
- Intracoronary radiation presents relative merits and disadvantages for ISR management.
- Advancements in drug-eluting stent technology offer significant promise for ISR eradication.
Conclusions:
- In-stent restenosis (ISR) remains a challenge following coronary stenting.
- Drug-eluting stents represent a promising future direction for effectively managing and potentially eliminating ISR.